

Marcos Oggero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6814357/publications.pdf>

Version: 2024-02-01

29
papers

286
citations

1039880

9
h-index

940416

16
g-index

29
all docs

29
docs citations

29
times ranked

435
citing authors

#	ARTICLE	IF	CITATIONS
1	Highly glycosylated human alpha interferon: An insight into a new therapeutic candidate. <i>Journal of Biotechnology</i> , 2010, 146, 74-83.	1.9	40
2	N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line. <i>FEBS Journal</i> , 2004, 271, 907-919.	0.2	39
3	A highly efficient modified human serum albumin signal peptide to secrete proteins in cells derived from different mammalian species. <i>Protein Expression and Purification</i> , 2017, 132, 27-33.	0.6	25
4	Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha mutein. <i>Biochimie</i> , 2010, 92, 971-978.	1.3	24
5	Improvement of in vitro stability and pharmacokinetics of hIFN- α 2 by fusing the carboxyl-terminal peptide of hCG β 2-subunit. <i>Journal of Biotechnology</i> , 2016, 221, 13-24.	1.9	17
6	WISH cell line: From the antiviral system to a novel reporter gene assay to test the potency of human IFN- α 2 and IFN- β 2. <i>Journal of Immunological Methods</i> , 2012, 381, 70-74.	0.6	16
7	Isolation and characterization of a subset of erythropoietin glycoforms with cytoprotective but minimal erythropoietic activity. <i>Biotechnology Progress</i> , 2011, 27, 1018-1028.	1.3	13
8	Glycosylation and antiproliferative activity of hyperglycosylated IFN- α 2 potentiate HEK293 cells as biofactories. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 112, 119-131.	2.0	13
9	A single monoclonal antibody as probe to detect the entire set of native and partially unfolded rhEPO glycoforms. <i>Journal of Immunological Methods</i> , 2004, 293, 191-205.	0.6	11
10	Defining the antigenic structure of human GM-CSF and its implications for receptor interaction and therapeutic treatments. <i>Molecular Diversity</i> , 2004, 8, 257-269.	2.1	10
11	High performance collection of cerebrospinal fluid in rats: Evaluation of erythropoietin penetration after osmotic opening of the blood-brain barrier. <i>Journal of Neuroscience Methods</i> , 2013, 219, 70-75.	1.3	9
12	Production of monoclonal antibodies in microfluidic devices. <i>Integrative Biology (United Kingdom)</i> , 2018, 10, 136-144.	0.6	9
13	Screening and characterization of molecules that modulate the biological activity of IFNs-I. <i>Journal of Biotechnology</i> , 2016, 233, 6-16.	1.9	8
14	Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases. <i>Clinical Immunology</i> , 2021, 233, 108888.	1.4	8
15	Novel erythropoietin-based therapeutic candidates with extra N-glycan sites that block hematopoiesis but preserve neuroplasticity. <i>Biotechnology Journal</i> , 2021, 16, e2000455.	1.8	6
16	Bifunctional GM-CSF-derived peptides as tools for O-glycoengineering and protein tagging. <i>Journal of Biotechnology</i> , 2021, 327, 18-27.	1.9	6
17	New reporter cell clones to determine the biological activity of human type I interferons. <i>BMC Proceedings</i> , 2011, 5, P4.	1.8	5
18	Pharmacokinetics Versus In Vitro Antiproliferative Potency to Design a Novel Hyperglycosylated hIFN- α 2 Biobetter. <i>Pharmaceutical Research</i> , 2021, 38, 37-50.	1.7	4

#	ARTICLE	IF	CITATIONS
19	Neuroprotective activity of a new erythropoietin formulation with increased penetration in the central nervous system. BMC Proceedings, 2011, 5, P3.	1.8	3
20	Strategies to Develop Therapeutic N- and O-Hyperglycosylated Proteins. Methods in Molecular Biology, 2018, 1674, 163-181.	0.4	3
21	Effect of ANITVNITV peptide fusion on the bioactivity and pharmacokinetics of human IFN- β and a hyper-N-glycosylated variant. Journal of Biotechnology, 2019, 303, 46-52.	1.9	3
22	The glycosylation of anti-rhIFN- β recombinant antibodies influences the antigen-neutralizing activity. Biotechnology Letters, 2020, 42, 1369-1381.	1.1	3
23	Rational selection of an antibody probe to detect the heterogeneous collection of CHO-derived rhGM-CSF glycoforms. Biotechnology Letters, 2006, 28, 2049-2056.	1.1	2
24	A versatile ionic strength sensitive tag from a human GM-CSF-derived linear epitope. Protein Expression and Purification, 2013, 91, 10-19.	0.6	2
25	Design and validation of an immuno-PCR assay for IFN- β quantification in human plasma. Bioanalysis, 2019, 11, 2175-2188.	0.6	2
26	Identification and characterization of human interferon alpha inhibitors through a WISH cell line-based reporter gene assay. Bioorganic Chemistry, 2020, 94, 103372.	2.0	2
27	Large Area Microfluidic Bioreactor for Production of Recombinant Protein. Biosensors, 2022, 12, 526.	2.3	2
28	An unusual cysteine V L 87 affects the antibody fragment conformations without interfering with the disulfide bond formation. Molecular Immunology, 2017, 90, 143-149.	1.0	1
29	6.2 High Cell Density Cultivation Process. , 2014, , 427-454.		0